Compare HLF & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLF | OGN |
|---|---|---|
| Founded | 1980 | 1923 |
| Country | United States | United States |
| Employees | N/A | 10000 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2004 | 2020 |
| Metric | HLF | OGN |
|---|---|---|
| Price | $15.50 | $6.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $17.00 | $11.75 |
| AVG Volume (30 Days) | 1.7M | ★ 3.1M |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.20 | 0.72 |
| Revenue | $5,037,500,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $4.91 | $0.42 |
| Revenue Next Year | $3.90 | $1.67 |
| P/E Ratio | ★ $7.13 | $8.99 |
| Revenue Growth | ★ 0.89 | N/A |
| 52 Week Low | $6.20 | $6.18 |
| 52 Week High | $20.40 | $15.88 |
| Indicator | HLF | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 31.58 |
| Support Level | $14.59 | $6.18 |
| Resistance Level | $17.80 | $7.87 |
| Average True Range (ATR) | 0.77 | 0.22 |
| MACD | -0.36 | -0.04 |
| Stochastic Oscillator | 17.61 | 11.52 |
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.